Neurocrine Biosciences Gets FDA Breakthrough Therapy Status for Genetic Disorder Treatment
By Ben Glickman
Neurocrine Biosciences has received breakthrough therapy designation for its treatment for congenital adrenal hyperplasia from the U.S. Food and Drug Administration.
The San Diego-based biotechnology company said Tuesday it was on track to submit a new drug application for crinecerfont in the treatment of congenital adrenal hyperplasia, a genetic disorder, in 2024.
The company announced it was on track to advance two gene therapies into the clinic in 2025, and expects to have more than 20 development candidates by 2027.
Chief Medical Officer Eiry Roberts said the FDA designation for crinecerfont was an acknowledgement of the seriousness of congenital adrenal hyperplasia and the unmet need faced by patients.
Breakthrough therapy designation is given by the FDA to speed up development of treatments for serious conditions that show preliminary evidence of effectiveness.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 05, 2023 16:38 ET (21:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now